A Cochrane review [Abstract] 1 included 7 RCTs with a total of 2061 patients to compare the efficacy and safety of toremifene (TOR) with tamoxifen (TAM) in patients with advanced breast cancer.
1226 patients were in the TOR group and 835 patients in the TAM group. In the pooled analysis, the objective response rates (ORR) were not statistically different between the two groups (RR 1.02, 95% CI 0.88 to 1.18). The median time to progression (TTP) was 6.1 months for the TOR group and 5.8 months for the TAM group. The median overall survival (OS) was 27.8 months for the TOR group and 27.6 months for the TAM group. There were no significant differences between the two therapeutic groups in time to progression (TTP; HR 1.08, 95% CI 0.94 to 1.24) or overall survival (OS: HR 1.02, 95% CI 0.86 to 1.20). The frequencies of most adverse events were also similar in the two groups, while headache seemed to occur less in the TOR group than in the TAM group (RR 0.14, 95% CI 0.03 to 0.74).
Date of latest search:
Primary/Secondary Keywords